Premium
Potential Use of Erythromycin to Prevent and Treat Prosthetic Failure
Author(s) -
Zhang Peng,
Qin Ling
Publication year - 2010
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270009360535
Subject(s) - medicine , osteolysis , erythromycin , aseptic processing , life span , intensive care medicine , joint replacement , surgery , orthopedic surgery , antibiotics , arthroplasty , gerontology , microbiology and biotechnology , biology
Prolonged prosthetic life span is a goal that orthopedic surgeons are pursuing. Both septic and aseptic loosening may lead to prosthetic failure. For decades, antibiotics have been applied in arthroplasty to prevent septic loosening, with excellent clinical results, although few therapies have been able to prevent aseptic loosening. Research on aseptic loosening indicates that osteoclasts play an essential role in this process. Thus, the exploration of osteoclastogenesis inhibitor has become of interest. Erythromycin is a broad‐spectrum antimicrobial that has been used to prevent postoperative infection after artificial joint replacement. A new function to inhibit particle‐induced osteolysis has been discovered recently. Fundamental research indicates that erythromycin administration should be an excellent method for the prophylaxis of prosthetic failure and should increase the life span of artificial joint in clinics.